Endospan is a brand that aims to establish itself as a dominant competitor in the endovascular aortic repair market. With a team of experienced researchers, engineers, and executives in the MedTech field, Endospan is backed by leading global venture groups in its pursuit of innovation and excellence. The brand's platform presents a groundbreaking solution for repairing aneurysms and dissections in patients with previously unsuitable anatomy for endovascular therapy.

What sets Endospan apart is its novel design, which surpasses traditional EVAR/TEVAR systems in terms of durability, intra-procedural stability, and a shorter, simpler, and less invasive procedure. Their endografts are enhanced with gold-standard material, providing the highest level of reliability. Endospan's leadership team is comprised of accomplished professionals with diverse expertise.

From the Chief Executive Officer, Kevin Mayberry, who has extensive experience in R&D and global sales management, to the General Manager Ami Katz, with a strong background in operations management, production, and product management, the team ensures that Endospan delivers on its promises. With a commitment to research and development, led by Ian McDougall, Vice President of Research & Development, Endospan stays at the forefront of the industry, delivering innovative solutions that have undergone rigorous clinical trials and received market approval. Pieter Buyl, Vice President of Sales and Marketing, heads the efforts to reach interventional cardiology, vascular, and cardiac surgery markets.

His extensive experience in international sales and marketing positions, including leading the efforts for CE mark and FDA approval at a start-up company, showcases Endospan's dedication to growth and success. Additionally, the brand benefits from the expertise of Jessica Kleine, Vice President of Clinical Affairs, who brings a wealth of experience in clinical research. Her leadership roles in various fields, including the development of novel medical devices, contribute to Endospan's commitment to advancing patient care.

With Gadi Divald as the Chief Financial Officer, Endospan combines financial acumen with business strategy. His extensive experience as a finance and business executive, along with his international track record, ensures the brand's financial stability and growth. Mario Lachat, the Medical Director of NEXUS, is an early adopter of the Horizon and Nexus Stentgraft systems.

With expertise in complex open surgery and endoaortic procedures, he has published numerous relevant papers and conducted national and international studies. His involvement ensures the safety and effectiveness of Endospan's devices. In summary, Endospan is a brand committed to pushing the boundaries of endovascular aortic repair.

With its innovative platform and a team of seasoned professionals, Endospan aims to provide advanced solutions for patients with aneurysms and dissections, ultimately improving their quality of life